Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03528707
Recruitment Status : Completed
First Posted : May 18, 2018
Last Update Posted : December 17, 2019
Sponsor:
Information provided by (Responsible Party):
Nazarii Kobyliak, Bogomolets National Medical University

Brief Summary:
One of the potential ideal strategy for NAFLD treatment may be manipulation with gut microbiota. Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Omega-3 fatty acids belong to the family of polyunsaturated fatty acids. They are known to exert a strong positive influence on metabolism and inflammation. The data from animal studies suggested that both probiotics and omega-3 can affect body weight, influence on glucose and fat metabolism, improve insulin sensitivity and reduce chronic systemic inflammation. In respect to experimental data, the current study aim was to provide double-blind single center RCT, for study the efficacy of co-administration of probiotic with omega-3 vs. placebo in type 2 diabetes patient with NAFLD detected on ultrasonography

Condition or disease Intervention/treatment Phase
Type2 Diabetes NAFLD Probiotic Omega-3 Fatty Acids Dietary Supplement: Symbiter-Omega Dietary Supplement: Placebo Not Applicable

Detailed Description:

In this single-center double-blind, placebo controlled, parallel group study, 48 type 2 diabetes patients from the Kyiv City Clinical Endocrinology Center were selected. They were randomly assigned to receive "Symbiter Omega" or placebo for 8 weeks, administered as a sachet formulation in double-blind treatment. Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.

The "Symbiter Omega" was supplied by Scientific and Production Company "O.D. Prolisok". It contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic-omega and placebo per day. All sachets were identical with similar organoleptic characteristics (e.g., taste and appearance).

The pre-randomization period was designed to minimize the effects of dietary changes on metabolic markers. For this purpose, 2 weeks before the study start, after inform consent signed, patients were instructed in one-on-one sessions with a dietitian to follow a therapeutic lifestyle-change diet as classified by the NCEP. In addition, participants were instructed to continue with stable anti-hyperglycemic treatment and received standardized mild physical training for 1 hour per day.

Patients who underwent the study were instructed to take the trial medication as prescribed. Throughout the study, weekly phone follow-up visits were provided for assessment of compliance, adherence to the protocol, as well as the recording of adverse events. The effectiveness of therapy was compared and evaluated separately in the two groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.
Primary Purpose: Treatment
Official Title: Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD: Randomized Clinical Studies
Actual Study Start Date : April 14, 2015
Actual Primary Completion Date : December 22, 2015
Actual Study Completion Date : January 28, 2016


Arm Intervention/treatment
Active Comparator: probiotic-omega
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
Dietary Supplement: Symbiter-Omega
"Symbiter Omega" which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101

Placebo Comparator: placebo
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Dietary Supplement: Placebo
Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day




Primary Outcome Measures :
  1. fatty liver index (FLI) [ Time Frame: 8 weeks compared to baseline ]
    FLI = [e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745)] × 100

  2. liver stiffness (LS) [ Time Frame: 8 weeks compared to baseline ]
    liver stiffness (LS) was measured by Shear Wave Elastography (SWE) and expressed in kPa.


Secondary Outcome Measures :
  1. ALT [ Time Frame: 8 weeks compared to baseline ]
    ALT in IU/L

  2. AST [ Time Frame: 8 weeks compared to baseline ]
    AST in IU/L

  3. γ-GT [ Time Frame: 8 weeks compared to baseline ]
    γ-GT in IU/L

  4. Total Cholesterol (TC) [ Time Frame: 8 weeks compared to baseline ]
    TC in mmol/l

  5. Tryglicerides (TG) [ Time Frame: 8 weeks compared to baseline ]
    TG in mmol/l

  6. LDL-Cholesterol (LDL-C) [ Time Frame: 8 weeks compared to baseline ]
    LDL-C in mmol/l

  7. VLDL-Cholesterol (VLDL-C) [ Time Frame: 8 weeks compared to baseline ]
    VLDL-C in mmol/l

  8. HDL-Cholesterol (HDL-C) [ Time Frame: 8 weeks compared to baseline ]
    HDL-C in mmol/l

  9. cytokines levels [ Time Frame: 8 weeks compared to baseline ]
    TNF-α, IL-1β, IL-6, IL-8, INF-γ in pg/ml



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult participants (ages 18-75, BMI ≥25 kg/m2) diagnosed with NAFLD according to the recommendations of the American Gastroenterology Association (AGA) and American Association for the Study of Liver Disease (AASLD);
  • the diagnosis of fatty liver was based on the results of abdominal ultrasonography. Of 4 known criteria (hepato-renal echo contrast, liver brightness, deep attenuation, and vascular blurring), the participants were required to have hepato-renal contrast and liver brightness to be given a diagnosis of NAFLD.
  • type 2 diabetes treated with diet and exercise alone or metformin, SUs and insulin at stable dose at least 4 weeks prior to the commencement of the study;
  • AST and ALT ≤3x upper limit of normal.

Exclusion Criteria:

  • alcohol abuse (>20 g/day (2 standard drinks) in women or > 30 g/d (3 drinks) in men over a two-year period);
  • chronic viral hepatitis (associated with HBV, HCV, HDV infection);
  • drug-induced liver disease, Wilson's disease, hereditary deficiency of antitrypsin-1 and idiopathic hemochromatosis;
  • history of decompensated liver disease including ascites, encephalopathy or variceal bleeding;
  • regular use of a probiotic or prebiotic supplement within 3 months prior to enrollment;
  • antibiotic use within 3 months prior to enrollment;
  • uncontrolled cardiovascular or respiratory disease, active malignancy, or chronic infections;
  • use of agents such as vitamin E, omega-3 fatty acids or medications with evidence for effects on NAFLD (pioglitazone, GLP-1 analogues, dipeptidyl peptidase IV inhibitors, ursodeoxycholic acid);
  • and presence of active infection, pregnancy or lactation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528707


Sponsors and Collaborators
Bogomolets National Medical University
Investigators
Layout table for investigator information
Principal Investigator: Galyna Mykhalchyshyn, PhD Bogomolets National Medical University
Publications of Results:
Layout table for additonal information
Responsible Party: Nazarii Kobyliak, Associate Professor of Endocrinology Department, PhD, Bogomolets National Medical University
ClinicalTrials.gov Identifier: NCT03528707    
Other Study ID Numbers: ENDO-2
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: December 17, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Non-alcoholic Fatty Liver Disease
Fatty Liver
Liver Diseases
Digestive System Diseases